The Lancet Diabetes & Endocrinology
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
By Christopher H. Sorli, Shin-ichi Harashima, George M. Tsoukas, Show 3 more authorsStephen Charles Bain
Randomised trial in 387 peopleInterventions
30 weeks, double-blind, placebo-controlled, multicentre, registered NCT02054897
The paper
Billings Clinic; Swansea University
The Lancet Diabetes & Endocrinology, 17 Jan 2017
